Zurich Cantonal Bank’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
VPM
VCM
MCMU
Zurich Cantonal Bank's RXRX Position: Q1 2026 in Review
Zurich Cantonal Bank opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 214,851 shares worth $660K. The stake represents ﹤0.01% of the portfolio and ranks #1673 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in RXRX as recently as Q3 2025.
Zurich Cantonal Bank first reported a position in RXRX in Q3 2021 and has held it in 17 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.
- Zurich Cantonal Bank held 214,851 shares of Recursion Pharmaceuticals worth $660K as of Q1 2026.
- Recursion Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
- Recursion Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1673 holding.
- Zurich Cantonal Bank first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
- 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.
Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.